Showing 20 of 200 recruiting trials for “large-granular-lymphocyte-leukemia”
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
👨⚕️ Sanbin Wang, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China📍 1 site📅 Started Jun 2024View details ↗
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
👨⚕️ Jianxiang Wang, Dr, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jun 2024View details ↗
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 73 sites📅 Started May 2024View details ↗
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Vitamin A and D Supplementation in Allogeneic HCT
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
👨⚕️ Xiaowen Tang, Ph.D, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Apr 2024View details ↗
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
👨⚕️ Jianyong Li, PhD, MD, The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Apr 2024View details ↗
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
👨⚕️ Lugui Qiu, M.D., Ph.D., Hematology Hospital of the Chinese Academy of Medical Sciences📍 6 sites📅 Started Apr 2024View details ↗
RecruitingNCT06025682 ↗
Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO
👨⚕️ Livio Pagano, Policlinico Universitario A. Gemelli, IRCCS-Università Cattolica del Sacro Cuore, Roma📍 1 site📅 Started Apr 2024View details ↗
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
👨⚕️ Aimee C. Talleur, MD, St. Jude Children's Research Hospital📍 1 site📅 Started Feb 2024View details ↗
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →